Financing ·
Raises $4M via private placement and warrant exercise; signs CDMO deal with $5.1M in base fees
SCNIScinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd. completed a financing transaction generating approximately $3.6 million in net proceeds, consisting of a private placement and the cash exercise of existing warrants. The company also announced a new contract development and manufacturing organization (CDMO) agreement with a U.S.-based biopharmaceutical customer, securing approximately $5.1 million in committed base service fees. This deal expanded Scinai's Committed Customer Orders to roughly $8.1 million as of October 20, 2026, up from $1.9 million at year-end 2025. Combined with the financing proceeds and expected customer payments, management estimates an operating runway extending to late 2027, potentially into mid-2028 if later project phases are activated. Scinai Immunotherapeutics Ltd. operates a contract development and manufacturing business alongside an immunology-focused therapeutic development platform.